The natural history of progressive fibrosing interstitial lung diseases
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
We used data from the INBUILD and INPULSIS trials to investigate the natural history of progressive fibrosing interstitial lung diseases (ILDs). Subjects in the two INPULSIS trials had a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) while subjects in the INBUILD trial had a progressive fibrosing ILD other than IPF and met protocol-defined criteria for ILD progression despite management. Using data from the placebo groups, we compared the rate of decline in forced vital capacity (FVC) (mL·year −1 ) and mortality over 52 weeks in the INBUILD trial with pooled data from the INPULSIS trials. The adjusted mean annual rate of decline in FVC in the INBUILD trial (n=331) was similar to that observed in the INPULSIS trials (n=423) (−192.9 mL·year −1 and −221.0 mL·year −1 , respectively; nominal p-value=0.19). The proportion of subjects who had a relative decline in FVC >10% predicted at Week 52 was 48.9% in the INBUILD trial and 48.7% in the INPULSIS trials, and the proportion who died over 52 weeks was 5.1% in the INBUILD trial and 7.8% in the INPULSIS trials. A relative decline in FVC >10% predicted was associated with an increased risk of death in the INBUILD trial (hazard ratio 3.64) and the INPULSIS trials (hazard ratio 3.95). These findings indicate that patients with fibrosing ILDs other than IPF, who are progressing despite management, have a subsequent clinical course similar to patients with untreated IPF, with a high risk of further ILD progression and early mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At this point, no biomarker or clinical prediction algorithm has been established as a reliable predictor for disease outcome or response to therapy in ILD.(233)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [233]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationNintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib is an intracellular inhibitor of tyrosine kinases [10, 25].”
BackgroundMechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 1×
“Along with these clinical similarities, progressive fibrosing ILDs appear to share pathobiological mechanisms that may represent a common fibrotic response to tissue injury [6-10].”
BackgroundSelf-citationUsual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Kim, E. J., Elicker, B. M., Maldonado, F., Webb, W. R., Ryu, J. H., Van Uden, J. H., Lee, J. S., King, T. E., & Collard, H. R. (2010) · European Respiratory Journal · doi:10.1183/09031936.00092309 · Cited by 587 · cited 2×
“Previous studies have suggested that in patients with fibrosing ILDs, the presence of a UIP-like fibrotic pattern on HRCT is associated with more rapid disease progression [11, 29-32].”
BackgroundWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527 · cited 1×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citationPredictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388 · cited 2×
“Declines in FVC of >10% and >5% predicted have been associated with mortality in patients with IPF [33, 34] and other chronic fibrosing ILDs [19-22].”
BackgroundSelf-citation
Cited by
Items 101–200 of 300
Takizawa, A., Kamita, M., Kondoh, Y., Bando, M., Kuwana, M., & Inoue, Y. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1860920 · Cited by 15
Current perspective of progressive-fibrosing interstitial lung disease
Kishaba, T. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.03.004 · Cited by 16
Kolb, M. R. J., Flaherty, K. R., Silva, R. S., Prasse, A., Vancheri, C., Mueller, H., Sroka, K., Wells, A. U., & on behalf of the INBUILD trial investigators (2023) · Advances in Therapy · doi:10.1007/s12325-023-02668-x · Cited by 17
Self-citationRavaglia, C., & Nicholson, A. G. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000810 · Cited by 18
Barnes, H., Corte, T. J., Keir, G. J., Khor, Y. H., Limaye, S., Wrobel, J. P., Veitch, E. M., Harrington, J., Dowman, L., Beckert, L., et al. (2024) · Respirology · doi:10.1111/resp.14847 · Cited by 16
“12,175 When determining suitability for referral to a lung transplant centre, considerations should include comorbidities, prognosis, transplant risk and patient goals.”
Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review
Montero, I. E., Hernández‐González, F., & Sellarés, J. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00302-5 · Cited by 15
Defining and predicting progression in non-IPF interstitial lung disease
Goos, T., Sadeleer, L. D., Yserbyt, J., Langhe, E. D., Dubbeldam, A., Verbeken, E. K., Verleden, G. M., Vermant, M., Verschakelen, J., Vos, R., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106626 · Cited by 14
Transbronchial lung cryobiopsy for the diagnosis of interstitial lung diseases
Ravaglia, C., & Poletti, V. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000848 · Cited by 13
Olson, A. L., Hartmann, N., Patnaik, P., Garry, E. M., Bohn, R. L., Singer, D., Baldwin, M., & Wallace, L. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02066-9 · Cited by 13
“A recent analysis of the placebo arms of three clinical trials (INBUILD and INPULSIS-1 and -2) found that patients with chronic fibrosing ILDs with a progressive phenotype other than IPF had a very similar disease course to patients with IPF in terms of forced vital capacity decline and risk of mortality [18].”
MethodLangford, B., Diamantopoulos, A., Maher, T. M., Inoue, Y., Rohr, K. B., & Baldwin, M. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02014-z · Cited by 13
“IPF is similar to other PF-ILDs in terms of the rate of FVC decline [2, 3, 12, 13].”
Piotrowski, W. J., Martusewicz-Boros, M. M., Białas, A. J., Barczyk, A., Batko, B. P., Błasińska, K., Boros, P. W., Górska, K., Grzanka, P., Jassem, E., et al. (2022) · Advances in respiratory medicine · doi:10.3390/arm90050052 · Cited by 15
“The poor prognosis of PF-ILDs other than IPF (which, in fact, is identical to the prognosis in IPF patients) and data from clinical trials demonstrating the beneficial effect of anti-fibrotic therapy (at this point, regarding nintedanib) support the isolation of this phenotype, which is common for the above-defined di…”
BackgroundResultInfluentialCriteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart
Cottin, V. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202208-1639ed · Cited by 17
Self-citationZhang, Z., Ma, X., Bai, J., Xia, S., Han, Q., & Luo, Q. (2023) · Rheumatology · doi:10.1093/rheumatology/kead409 · Cited by 13
“Therefore, researchers have termed ILD with progressive phenotype ‘PF-ILD’ [6, 10, 31].”
BackgroundResultSerum KL-6 as a biomarker to predict progression at one year in interstitial lung disease
Bonella, F., Sanchez, M. C. V., d’Alessandro, M., Millan‐Billi, P., dos Santos, R. F., Schröder, N., Bastos, H. N., Molina‐Molina, M., Sánchez‐Pernaute, O., Castillo, D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22483-4 · Cited by 15
Hoffmann‐Vold, A., Assassi, S., Cottin, V., Kreuter, M., Valenzuela, C., Wijsenbeek, M. S., Gu, H., Kanakapura, M., Ritter, I., Stowasser, S., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.03.027 · Cited by 14
Self-citationCOVID-19: the new cause of dyspnoea as a result of reduced lung and peripheral muscle performance
Acar, R. D., Sarıbaş, E., Güney, P. A., Kafkas, Ç., Aydınlı, D., Taşçı, E., & Kırali, M. K. (2021) · Journal of Breath Research · doi:10.1088/1752-7163/ac22bb · Cited by 12
Lobo, L. J., Liu, Y., Li, P., Ramaswamy, M., Swaminathan, A. C., Veeraraghavan, S., Fan, Y., Neely, M. L., Palmer, S. M., Olson, A. L., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03247-8 · Cited by 12
The progressive fibrotic phenotype in current clinical practice
Wells, A. U., Brown, K. K., & Cottin, V. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000805 · Cited by 12
Self-citationTreatment patterns and patient journey in progressive pulmonary fibrosis: a cross-sectional survey
Chaudhuri, N., Spagnolo, P., Valenzuela, C., Amatto, V. C., Carter, O.-T., Lee, L., Small, M., & Kreuter, M. (2024) · Respiratory Research · doi:10.1186/s12931-024-02995-9 · Cited by 11
“Regardless of the underlying condition, PPF occurs through similar mechanisms of self-sustained dysregulated cell repair, fibroblast proliferation and alveolar dysfunction [3, 17].”
BackgroundMononen, M., Saari, E., Hasala, H., Kettunen, H.-P., Suoranta, S., Nurmi, H., Kärkkäinen, M. S., Selander, T. A., Randell, J. T., Laurikka, J. O., et al. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02105-9 · Cited by 12
“In addition, it has been demonstrated that non-IPF ILD patients with disease progression have similar survival than patients with IPF [7, 8].”
ResultNakamura, Y., Shimizu, Y., Fujimaki, M., Uchida, N., Takemasa, A., & Niho, S. (2023) · Biomedicines · doi:10.3390/biomedicines11082259 · Cited by 11
“fibrosis (IPF), which chronically worsens, is 3–5 years [8,9]; FILD follows a course similar to that seen in IPF [10].”
BackgroundInfluentialKrebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases
Lederer, C., Mayer, K., Somogyi, V., Kriegsmann, K., Kriegsmann, M., Buschulte, K., Polke, M., Findeisen, P., Herth, F. J. F., & Kreuter, M. (2023) · Respiration · doi:10.1159/000531945 · Cited by 11
Figueiredo, R. G., Duarte, N. F. V., Campos, D. C. B., Verduzco, M. D. J. D., Márquez, Á. A., de Araújo, G. T. B., & Rubin, A. S. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21050647 · Cited by 11
“Progressive pulmonary fibrosis (PPF) share pathophysiological features with IPF [2,9,18].”
BackgroundThe Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases
Paul, D., Miller, M. H., Born, J. R., Samaddar, S., Ni, H., Avila, H., Krishnamurthy, V. R., & Thirunavukkarasu, K. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2160439 · Cited by 12
“The most extensively studied and aggressive form of ILD, idiopathic pulmonary fibrosis (IPF), has a poor prognosis and a median survival of 3–5 years if left untreated [2].”
BackgroundThe justification for the progressive fibrotic phenotype
Kolb, M. R. J., & Flaherty, K. R. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000803 · Cited by 11
“The most striking evidence is from the INBUILD trial, which demonstrated that patients with a variety of non-IPF ILD, which were progressive despite conventional therapies, lost on average approximately 190 ml FVC in one year, which is almost identical to what is known for IPF [16].”
BackgroundRisk factors for progression of pulmonary fibrosis: a single-centered, retrospective study
Fan, J.-J., Gu, J.-M., Xiao, S.-Y., Jia, M., & Han, G.-L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1335758 · Cited by 11
Cicco, S., Vacca, A., Cittadini, A., & Marra, A. M. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.3.407 · Cited by 10
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.014 · Cited by 14
Self-citationCorrelation between CT-based phenotypes and serum biomarker in interstitial lung diseases
Shin, B., Oh, Y. J., Kim, J., Park, S. G., Lee, K. S., & Lee, H. Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03344-8 · Cited by 9
“Thus, early diagnosis and accurate assessment of ILD severity are crucial for initiating treatment, monitoring disease progression, and predicting prognosis [2].”
BackgroundDiagnosis and Management of Interstitial Lung Disease in Patients with Connective Tissue Diseases
Koslow, M., Maleki-Fischbach, M., & Keith, R. C. (2021) · Case Reports in Rheumatology · doi:10.1155/2021/6677353 · Cited by 9
Nakamura, Y., Niho, S., & Shimizu, Y. (2024) · Cells · doi:10.3390/cells13110893 · Cited by 9
“IPF is reported to be chronically progressive, with a median survival of 3 to 5 years after diagnosis [1,2], and to have a similar course to progressive FILD [15].”
BackgroundPerformance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis
Newton, C. A., Thenappan, A., Liu, G. Y., Yazbeck, L., Lee, C. T., Pugashetti, J. V., Wang, J. M., White, E., Flaherty, K. R., Belloli, E. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202501-0317oc · Cited by 9
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., et al. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231165912 · Cited by 8
Callahan, S. J., Scholand, M. B., Kalra, A., Muelly, M. C., & Reicher, J. J. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.021 · Cited by 8
Diken, Ö. E., Güngör, Ö., & Akkaya, H. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03226-z · Cited by 8
“Interstitial lung diseases (ILD) are a heterogeneous group of more than 200 pulmonary diseases that affect the lung parenchyma [1].”
BackgroundNeurocognitive and Neuropsychiatric Implications of Fibrosing Interstitial Lung Diseases
Vastag, Z., Tudorache, E., Trăilă, D., Firă-Mladinescu, O., Marc, M. S., Oancea, C. I., & Roşca, E. C. (2024) · Biomedicines · doi:10.3390/biomedicines12112572 · Cited by 8
Kilpeläinen, M., Hirvonen, T., Perkonoja, K., & Hirsjärvi, S. (2023) · Medicina · doi:10.3390/medicina59020281 · Cited by 8
Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox
Nagy, A., Palmer, E., Polivka, L., Eszes, N., Vincze, K., Bárczi, E., Bohács, A., Tárnoki, Á. D., Tárnoki, D. L., Nagy, G., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020434 · Cited by 8
Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed)
Cottin, V., & Valenzuela, C. (2022) · European Respiratory Journal · doi:10.1183/13993003.01449-2022 · Cited by 8
Self-citationClinical Overview of Progressive Fibrotic Interstitial Lung Disease
Case, A. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.858339 · Cited by 8
“Though not formally defined, features that suggest progressive fibrosing ILD (PF-ILD) include decline in lung function as measured by forced vital capacity (FVC) or diffusing capacity of the lung for carbon monoxide (DLCO), radiographic progression of fibrotic features on high resolution computed tomography (HRCT), or…”
BackgroundMoran‐Mendoza, O., Singla, A., Kalra, A., Muelly, M. C., & Reicher, J. J. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.05.010 · Cited by 8
Diagnosis of interstitial lung diseases: from Averill A. Liebow to artificial intelligence
Yi, E. S., Wawryko, P., & Ryu, J. H. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.17 · Cited by 7
Compare three diagnostic criteria of progressive pulmonary fibrosis
Chen, T., & Zeng, C. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-481 · Cited by 9
Fanshawe, J. B., Howell, J., Omar, A., Piper, M., & Simpson, T. (2021) · Physiotherapy Research International · doi:10.1002/pri.1903 · Cited by 7
Synthesis and evaluation of new pirfenidone derivatives as anti-fibrosis agents
Gu, C., Li, W., Ju, Q., Yao, H., Yang, L., An, B., Hu, W., & Li, X. (2022) · RSC Advances · doi:10.1039/d2ra00990k · Cited by 7
Kam, M. L. W., Tiew, P. Y., Chai, H. Z., & Low, S. Y. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-40 · Cited by 8
Singer, D., Chastek, B. J., Sargent, A., Johnson, J., Shetty, S. S., Conoscenti, C., & Bernstein, E. J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02637-8 · Cited by 6
“Chronic fibrosing ILD may be described as a fibro-pro-liferative or inflammatory condition and may be associated with several autoimmune disorders, infections, or environmental exposures [5].”
BackgroundOatis, D. A., Herman, H., Baltă, C., Ciceu, A., Simon-Repolski, E., Mihu, A. G., Lepre, C. C., Russo, M., Trotta, M. C., Gravina, A. G., et al. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241236257 · Cited by 6
Fu, C., Tian, X., Wu, S., Chu, X., Cheng, Y., Wu, X., & Yang, W. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1447296 · Cited by 6
Westerink, L., Nicolai, J. L. J., Postma, M. J., van Boven, J. F. M., & Boersma, C. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00354-2 · Cited by 6
“found that patients with PF-ILD who received placebo in the INBUILD trial had a clinical course similar to patients with untreated IPF [40].”
ResultNovoa-Bolivar, E. M., Ros, J. A., Pérez‐Fernández, S., Campillo, J. A., López‐Hernández, R., González-López, R., Otálora-Alcaraz, A., Ortuño-Hernández, C., Gimeno, L., Ruiz-Lorente, I., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12112439 · Cited by 6
Wells, A. U., & Kouranos, V. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1968832 · Cited by 6
Self-citationPatterns of progression in non-IPF fibrotic interstitial lung disease
Wells, A. U. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000981 · Cited by 6
“trials, whereas FVC decline in INBUILD patients with other fibrotic patterns on CT had a significantly lesser rate of FVC progression [13].”
ResultSelf-citationProportion and predictors of FVC decline in patients with interstitial lung disease
MacMurdo, M. G., Ji, X., Pimple, P. M., Olson, A. L., Milinovich, A., Martyn-Dow, B., Pande, A., Zajichek, A., Bauman, J. M., Bender, S. D., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107656 · Cited by 5
Suzuki, K., Akiyama, M., Shimanuki, K., Fukui, H., & Kaneko, Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152891 · Cited by 5
Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary Fibrosis Lung Disease
Warrior, K., Chung, P. A., Reid, M., & Bemiss, B. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202012-4356rr · Cited by 5
Dhooria, S., Babu, V., Dhir, V., Sehgal, I. S., Prasad, K. T., Muthu, V., Bal, A., Debi, U., Garg, M. K., Agarwal, R., et al. (2022) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2022.08.004 · Cited by 5
Current best clinical practices for monitoring of interstitial lung disease
Bendstrup, E. M., Kronborg-White, S. B., Møller, J., & Prior, T. S. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2162504 · Cited by 7
Baratella, E., di Luca, V., Oliva, A., Fiorese, I., Segalotti, A., Troian, M., Lovadina, S., Ruaro, B., Salton, F., Polverosi, R., et al. (2025) · Medicina · doi:10.3390/medicina61122094 · Cited by 4
“This ensures appropriate multidisciplinary management and the timely introduction of anti-fibrotic treatments when necessary [19,79].”
Xiebai San mediates the NCOA2-ESR1/2 signaling pathway to intervene in interstitial pneumonia
Yao, Y., Shao, L., Li, Z., Liang, J., Zhu, C., Wang, S., Lin, C., & Liu, F. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157663 · Cited by 4
Кузубова, Н. А., Titova, O. N., & Sklyarova, D. B. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-17-99-106 · Cited by 4
Pugashetti, J. V., Kim, J. S., Combs, M. P., Ma, S., Adegunsoye, A., Linderholm, A., Strek, M. E., Chen, C., Dilling, D. F., Whelan, T. P. M., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.03.018 · Cited by 4
Kwon, B. S., Sin, S., Kim, K.-H., Park, J., Shin, B., Yoo, H., & Kim, Y. H. (2025) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2024.0190 · Cited by 4
Sakashita, A., Hirano, A., Fujii, W., Bassler, K. E., Tsuji, T., Kadoya, M., Omoto, A., Hiraoka, N., Imabayashi, T., Kaneko, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-17374-7 · Cited by 4
“To explore the relationship between systemic and pulmonary inflammation, we analyzed the correlations between plasma and BALF concentrations of biomarkers measured by ELISA in all 43 participants, using Spearman’s correlation coefficients (Supplementary Tables 4 and 5).”
Management and support of patients with fibrosing interstitial lung diseases
Barbera, T., Davila, L., & Patel, N. M. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000743332.64602.aa · Cited by 4
Biomarkers of Progressive Fibrosing Interstitial Lung Diseases
Валентиновна, Б. Е., & Yurkova, Y. G. (2023) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2023-8-4-126-133 · Cited by 5
Jang, J. H., Ko, J., Jung, S. Y., Kim, D.-W., Oh, J. H., Kim, T. J., Park, J. H., Choi, M., & Lee, J. H. (2023) · Life · doi:10.3390/life13122318 · Cited by 4
Höppner, J., Wollsching-Strobel, M., Schumacher, F., Windisch, W., & Berger, M. P. (2024) · Archives of Rheumatology · doi:10.46497/archrheumatol.2024.10105 · Cited by 4
“5,14 Accordingly, in this cohort, 50% of patients with a UIP pattern on HRCT showed a progressive disease.”
BackgroundKorean Guidelines for Diagnosis and Management of Interstitial Lung Diseases
Park, C., Yeo, Y., Woo, A., Yoo, J. W., Hong, G., Shin, J. W., Park, S. W., & on Behalf of the Korean Interstitial Lung Disease Study Group (2025) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2025.0044 · Cited by 6
Indications, pre-operative evaluation, and timing for lung transplantation listing
Baz, M. A., Pitts, M. D., & Keshavamurthy, S. (2021) · Current Challenges in Thoracic Surgery · doi:10.21037/ccts-20-170 · Cited by 4
Enfermedades pulmonares intersticiales
Serrano, M. P., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.010 · Cited by 4
Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis
Mira-Avendano, I. C., & Kaye, M. G. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241266343 · Cited by 4
Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”
Brown, K. M., Schlenker‐Herceg, R., & Wells, A. U. (2020) · European Respiratory Journal · doi:10.1183/13993003.03967-2020 · Cited by 4
Self-citationThe evolution of the European Respiratory Journal : weathering the publishing pandemic
Kolb, M. R. J., Chalmers, J. D., & Humbert, M. J. C. (2021) · European Respiratory Journal · doi:10.1183/13993003.00084-2021 · Cited by 4
Retrospective study of predictors of pulmonary fibrosis progression in hypersensitivity pneumonitis
Трушенко, Н. В., Suvorova, O., Pershina, E. S., Nekludova, G. V., Chikina, S. Y., Levina, I. A., Chernyaev, A. L., Samsonova, M. V., Tyurin, I. E., Nadtochiy, N. B., et al. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-137 · Cited by 3
Miceli, V., Callari, A., Calzolari, E., Castelbuono, S., Claudia, C., Lanzarone, N., Martino, L., Conaldi, P. G., Pinzani, M., & Vitulo, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-12952-1 · Cited by 3
Yamamoto, Y., Akamatsu, T., Hirai, K., & Shirai, T. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.101352 · Cited by 3
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-34071-7 · Cited by 3
Muscato, G., Libra, A., Reina, C., Gili, E., Fruciano, M., Martella, S., Palmucci, S., Spicuzza, L., Sambataro, G., & Vancheri, C. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04120-6 · Cited by 3
“PPF therefore represents an umbrella term encompassing fibrosing ILDs with a trajectory reminiscent of IPF [5].”
Pérez, E. R. F., Humphries, S. M., Lynch, D. A., Moua, T., Chaudhary, S., Adams, T. N., Adegunsoye, A., Scholand, M. B., Sood, N., & Vestal, B. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag116 · Cited by 3
Progressive pulmonary fibrosis: a state-of-the-art review
Cottin, V., Brown, K. K., Flaherty, K. R., Kolb, M. R. J., Lynch, D. A., Oldham, J. M., Valenzuela, C., Wijsenbeek, M. S., & Wells, A. U. (2026) · European Respiratory Journal · doi:10.1183/13993003.01557-2025 · Cited by 4
Self-citationChallenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease
Tolle, L. B. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/9942432 · Cited by 5
Chronic fibrosing interstitial lung diseases according to the register of Irkutsk (Russia)
Nashatyreva, M. S., Николаевна, Т. И., & Chernyak, B. A. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-2-199-207 · Cited by 3
PROGRESSIVE PULMONARY FIBROSIS IN LIGHT OF THE ATS/ERS/JRS/ALAT 2022 CLINICAL GUIDELINES
Gavrysyuk, V. K., Dziublyk, Y. O., Merenkova, E. O., Strafun, O. V., & Bychenko, O. V. (2022) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2022-30-4-51-57 · Cited by 3
Yao, J., Wang, J., Guo, L., Su, P., Li, J., & Li, B. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1465753 · Cited by 3
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Wongkarnjana, A., & Ryerson, C. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00894-2020 · Cited by 3
A call for evidence in connective tissue diseases-associated interstitial lung disease
Cottin, V., Lega, J., Coury, F., & Nasser, M. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105274 · Cited by 3
Self-citationOldham, J. M., & Cottin, V. (2025) · CHEST Journal · doi:10.1016/j.chest.2024.12.006 · Cited by 4
Self-citationResende, A. C. L., Cordero, S., Mancuzo, E. V., Storrer, K. M., Moreira, M. A. C., Baptista, F. M. D. A., Ferreira, R. G., Soares, M. R., & Pereira, C. (2025) · Cureus · doi:10.7759/cureus.80290 · Cited by 2
Impact of medications on lung function in fibrotic hypersensitivity pneumonitis
Abe, T., Okamoto, T., Shimamura, T., Ejima, M., Sonoda, S., Shirai, T., Ishizuka, M., Furusawa, H., Tateishi, T., Hanazawa, R., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.09.001 · Cited by 2
Akkurt, E. S., Özdemirel, T. Ş., Özyürek, B. A., Ensarıoğlu, K., Birben, Ö. D., & Zenbilli, E. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-04013-0 · Cited by 2
Cho, H. R., Chung, M. J., Choi, H., Kim, J., An, A.-R., Ahn, S. Y., Yoo, J. Y., Jin, G. Y., Lynch, D. A., & Chae, K. J. (2026) · Korean Journal of Radiology · doi:10.3348/kjr.2025.0977 · Cited by 2
“In addition, the prognosis of PPF is poor, with a decline in lung function and mortality rates comparable to those of IPF [7].”
Interstitial lung abnormalities: to treat or not to treat? The hamlet dilemma
Zanini, U., Franco, G., Pirotta, C., Passeri, E., Mazzotta, S. M., Ferrara, G., Mura, M., Faverio, P., & Luppi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1762243 · Cited by 2
“In these cases, treatment decisions should be individualised— balancing the risk of overtreatment and drug-related adverse effects against the potential benefit of early intervention to prevent future decline (69).”
Patient perspectives on knowledge gaps in hypersensitivity pneumonitis
Varadarajan, J., Edgar, A., O'Beirne, R., Paul, T. K., Krishnan, J. K., Kaner, R. J., Safford, M. M., & Aronson, K. I. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002487 · Cited by 2
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
“The hallmark of PF-ILDs is the relentless progression of fibrosis despite conventional treatments, leading to significant mortality [4].”
Molecular approach to the classification of chronic fibrosing lung disease—there and back again
Verleden, S. E., Braubach, P., Kühnel, M., Dickgreber, N. J., Brouwer, E., Tittmann, P., Laenger, F., & Jonigk, D. D. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02964-9 · Cited by 2
“Indeed, post hoc analysis of the placebo groups of major clinical trials demonstrated that patients with fibrotic DPLD other than IPF and actual IPF patients had a very similar clinical course with a high risk of further progression and high mortality [17].”
BackgroundResultMacisaac, S., & Kolb, M. R. J. (2021) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2021.1899775 · Cited by 2
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, O., Pertseva, T. O., Ostrovsky, M. M., Basanets, A. V., Bychenko, O. V., Dziublyk, Y. O., Konopkina, L., et al. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-1-5-33 · Cited by 4
Hyperpolarized Xenon MRI, Further Evidence of Its Use in Progressive Pulmonary Fibrosis?
Gleeson, F. V., & Fraser, E. (2022) · Radiology · doi:10.1148/radiol.221381 · Cited by 2
de Totero, D., Barisione, E., & Clini, E. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1389532 · Cited by 2
Metadata
- Authors
- Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., & Wells, A. U.
- Affiliations
- National Jewish Health (US)
- Imperial College London (GB)
- University of Alabama at Birmingham (US)
- Medizinische Hochschule Hannover (DE)
- Boehringer Ingelheim (Germany) (DE)
- Lyon 1 Université (FR)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- Corresponding author
- Brown, Kevin K.
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-03-26
- Volume
- 55
- Issue
- 6
- Pages
- 2000085
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC7315005
- OpenAlex
- W3013021754
- Semantic Scholar
- eeb975721a6bad50451a09c9b2ffa308b44a51aa
- Cited by
- 293
- References
- 35
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 46 · 2023: 41 · 2022: 66 · 2021: 62 · 2020: 12
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- progressive fibrosing interstitial lung disease, idiopathic pulmonary fibrosis, natural history (disease), forced vital capacity decline, mortality, ILD progression, INBUILD trial, INPULSIS trials
- MeSH terms
- Aged, Female, Humans, Indoles, Male, Middle Aged, Vital Capacity, Lung Diseases, Interstitial, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.